Market Intelligence, Clinical Progress, and High-Purity Reagents for Melanoma, Developmental Disorders, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EDNRB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length Lentivirus) | EDNRB Lentivirus Particles. Full-length ORF with native glycosylation for stable cell line generation. Endotoxin Controlled. | View EDNRB Products |
| Antigen (ECD-Fc / Mutant Protein) | EDNRB ECD-Fc or mutant protein for soluble binding assays. High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. | View EDNRB Products |
| Gene Delivery | EDNRB Promise-ORF / Lentivirus. Codon-optimized for mammalian expression, sequence verified. | View EDNRB Products |
| Counter-Screen | EDNRA (Endothelin Receptor A) Lentivirus. Essential for selectivity assays to distinguish ETA vs ETB specificity. | View EDNRA Products |
| Ligand | EDN1 / EDN3 Proteins. Native endothelin peptides for binding and activation assays. High Purity (>95%). | View EDN1 Products |
| Benchmark Ab | Anti-EDNRB Recombinant Antibody (Sequence of Benchmark Drug). Positive control for binding/blockade assays. Sequence Verified. | View EDNRB Products |
| Validator | EDNRB siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View EDNRB Products |
| Related Target A | SOX10. Master regulator of neural crest/melanocyte lineage; pathway synergy with EDNRB. | View SOX10 Products |
| Related Target B | MITF. Downstream transcription factor in melanoma pathways; pathway synergy with EDNRB. | View MITF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Integrity (7-TM structure) | HEK293 Expressed Lentivirus for Stable Cell Lines. Preserves native folding and glycosylation for accurate binding studies. |
| ETA/ETB Selectivity Screening | Matched EDNRA and EDNRB Ortholog Panel (Human/Mouse/Cyno). Sequence Verified, >95% purity for cross-reactivity assessment. |
| ADC Internalization Validation | High-Titer Lentivirus (>10^8 TU/ml) for generating EDNRB-high cell lines suitable for flow cytometry-based uptake assays. |
| Off-target Liability Control | Validated siRNA and benchmark antibodies included for target specificity confirmation in functional assays. |
Live EDNRB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EDNRB therapeutics is intensifying, with major players shifting focus from traditional EDNRA-targeted cardiovascular agents to selective EDNRB modulation in oncology. Unlike EDNRA, which dominates pulmonary arterial hypertension (PAH) treatment, EDNRB is emerging as a critical survival pathway in melanoma (particularly uveal melanoma) and neural crest-derived malignancies. First-generation EDNRB antagonists face selectivity challenges; the next wave of R&D is targeting antibody-drug conjugates (ADCs), bispecific modalities, and monoclonal antibodies that exploit EDNRB-mediated internalization or modulate the tumor microenvironment (TME). Additionally, EDNRB is being explored in glioblastoma for its role in immune suppression. As first-generation therapies reach the clinic, resistance mechanisms (e.g., receptor mutations such as rs12720160, rs5345, rs5346) are expected to drive demand for mutant-specific reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAH) | Actelion, J&J | Pulmonary Arterial Hypertension (PAH) | Selectivity Assay (Need EDNRA vs EDNRB panels) |
| Selective Antagonist | Preclinical Academic Consortia | Hirschsprung Disease, Chronic Pain | ET-A vs ET-B Selectivity Panel (Need both EDNRA and EDNRB proteins) |
| Antibody-Drug Conjugate (ADC) | Emerging Biotechs, Oncology-focused MNCs | Uveal Melanoma, Metastatic Melanoma, Glioblastoma | Internalization Assay (Requires high-expression EDNRB cell lines via Lentivirus) |
| Monoclonal Antibody / Biologic Modulators | Early-stage Startups | Solid Tumors (TME), Microvascular Dysfunction | Binding Affinity & Cross-species Reactivity (Human/Cyno/Mouse orthologs required for toxicology) |